Dengue fever

BMJ (Online)

Volumn 351, Issue , 2015, Pages

  Kularatne, Senanayake A M ^a  

^a UNIVERSITY OF PERADENIYA   (Sri Lanka)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CORTICOSTEROID; DENGUE VACCINE; COLLOID;

ACALCULOUS CHOLECYSTITIS; ACUTE APPENDICITIS; ACUTE KIDNEY FAILURE; ACUTE PANCREATITIS; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIGEN DETECTION; BLOOD TRANSFUSION; CLINICAL FEATURE; CONVALESCENCE; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DIAGNOSTIC IMAGING; DISEASE CLASSIFICATION; DISEASE SEVERITY; EARLY DIAGNOSIS; ENCEPHALITIS; FLUID THERAPY; HEMOPHAGOCYTIC SYNDROME; HEPATIC ENCEPHALOPATHY; HEPATITIS; HOSPITAL DISCHARGE; HUMAN; HYPERVOLEMIA; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INTENSIVE CARE; LABORATORY TEST; MEDICAL HISTORY; MYOCARDITIS; NONHUMAN; PATIENT CARE; PATIENT EDUCATION; PATIENT MONITORING; PHYSICAL EXAMINATION; POSTVIRAL FATIGUE SYNDROME; PREGNANCY; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; REVIEW; RHABDOMYOLYSIS; SCREENING TEST; SECONDARY PREVENTION; SEROLOGY; THROMBOCYTE TRANSFUSION; THROMBOCYTOSIS; TREATMENT INDICATION; VIRUS DETECTION; VIRUS TRANSMISSION; AEDES; ANIMAL; CHILD; COLLOID; DENGUE VIRUS; DISEASE CARRIER; FEMALE; PATHOPHYSIOLOGY; PREGNANCY COMPLICATIONS, INFECTIOUS; THERAPEUTIC USE;

ADRENAL CORTEX HORMONES; AEDES; ANIMALS; CHILD; COLLOIDS; DENGUE; DENGUE VACCINES; DENGUE VIRUS; FEMALE; FLUID THERAPY; HUMANS; INSECT VECTORS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 84946100941     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h4661     Document Type: Review

References (41)

1. World Health Organization, Regional Office for South-East Asia. Comprehensive guidelines for prevention and control of dengue and dengue haemorrhagic fever-revised and expanded edition. 2011. www.searo.who.int/entity/vector-borne-tropical-diseases/documents/SEAROTPS60/en/.
2. World Health Organization, Special Programme for Research and Training in Tropical Diseases (TDR). Dengue guidelines for diagnosis, treatment, prevention and control: new edition. 2009. http://whqlibdoc.who.int/publications/2009/9789241547871-eng.pdf?ua=1.
3. Kalayanarooj S, Vaughn DW, Nimmannitya S, et al. Early clinical and laboratory indicators of acute dengue illness. J Infect Dis 1997;176:313-21.
4. Halstead SB. Dengue. Lancet 2007;370:1644-52.
5. Guzman MG, Kouri G. Dengue and dengue haemorrhagic fever in America: lessons and challenges. J Clin Virol 2007;27:1-13.
6. Teixeira MG, Barreto M. Diagnosis and management of dengue: clinical review. BMJ 2009;339:1189-93.
7. Wilder-Smith A, Gubler DJ. Geographic expansion of dengue: the impact of international travel. Med Clin North Am 2008;92:1377-90.
8. Webster DP, Farrar J, Rowland-Jones S. Progress towards dengue vaccine. Lancet Infect Dis 2009;9:678-87.
9. Pichainarong N, Mongkalangoon N, Kalyanarooj S, et al. Relationship between body size and severity of dengue haemorrhagic fever among children aged 0-14 years. South East J Trop Med Public Health 2006;37:283-8.
10. Guzman MG, Kouri GP, Bravo J, et al. Dengue haemorrhagic fever in Cuba 1981, retrospective seroepidemiological study. Am J Trop Med Hyg 1990;42:179-84.
11. Stephenson JR. Understanding dengue pathogenesis: implication for vaccine design. Bull World Health Organ 2005;83:308-14.
12. Whitehorn J, Simmons CP. The pathogenesis of dengue. Vaccine 2011;29:7221-8.
13. Libraty DH, Young PR, Pickering D, et al. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with development of dengue haemorrhagic fever. J Infect Dis 2002;186:1165-8.
14. Baldacchino F, Caputo B, Chandre F, et al. Control methods against invasive Aedes mosquitoes in Europe: a review. Pest Manag Sci 2015, published online 21 May.
15. Villar L, Dayan GH, Arredondo-García JL, et al; CYD15 Study Group. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015;372:113-23.
16. Premaratne R, Pathmeswaran A, Amarasekara ND, et al. A clinical guide for early detection of dengue fever and timing of investigations to detect patients likely to develop complications. Trans R Soc Trop Med Hyg 2009;103:127-31.
17. Ministry of Health, Sri Lanka. Guidelines on management of dengue fever and dengue haemorrhagic fever in children and adolescents: revised and expanded edition. Nov. 2012. www.epid.gov. lk/web/images/pdf/Publication/gmdfca12.pdf.
18. Kalayanarooj S, Nimmanitya S, Suntayakorn S, et al. Can doctors make an accurate diagnosis of dengue infection at an early stage? Dengue Bull 1999;23:1-9.
19. Sawasdivorn S, Vibulvattanakit S, Sasavatpakdee M, et al. Efficacy of clinical diagnosis of dengue fever in paediatric age groups as determined by WHO case definition 1997 in Thailand. Dengue Bull 2001;25:56-64.
20. Lima Mda R, Nogueira RM, Schatzmayr HG, et al. Comparison of three commercially available dengue NS1 antigen capture assays for acute diagnosis of dengue in Brazil. PLoS Negl Trop Dis 2010;4:e738.
21. Centers for Disease Control and Prevention. Clinical guidance: dengue virus. Jun. 2014. www.cdc.gov/dengue/clinicalLab/clinical.html.
22. Ashley EA. Dengue fever. Trends Anaesth Crit Care 2011;1:39-41.
23. Dung NM, Day NP, Tam DT, et al. Fluid replacement in dengue shock syndrome: randomized, double-blind comparison of four intravenous fluid regimens. Clin Infect Dis 1999;29:787-94.
24. Ngo NT, Cao XT, Kneen R, et al. Acute management of dengue shock syndrome: randomized double-blind comparison of 4 intravenous fluid regimens in the first hour. Clin Infect Dis 2001;32:204-13.
25. Wills BA, Nguyen MD, Ha TL, et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med 2005;353:877-89.
26. Pouliot SH, Xiong X, Harille RM, et al. Maternal dengue and pregnancy outcomes: a systemic review. Obstet Gynecol Surv 2010;65:107-18.
27. Ministry of Health, Sri Lanka. Guidelines on management of dengue fever and dengue haemorrhagic fever in adults: revised and expanded edition. Nov. 2012. www.epid.gov. lk/web/images/pdf/Publication/guidelines-for-the-management-of-df-and-dhf-in-adults.pdf.
28. Rajapakse S. Corticosteroids in the treatment of dengue illness. Trans R Soc Trop Med Hyg 2009;103:122-6.
29. Kularatne SA, Patirage MM, Pathirage PV, et al. Cardiac complication of a dengue fever outbreak of Sri Lanka, 2005. Trans R Soc Trop Med Hyg 2007;101:804-8.
30. Kularatne SA, Pathirage MM, Gunasena S. A case series of dengue fever with altered consciousness and electroencephalogram changes in Sri Lanka. Trans R Soc Trop Med Hyg 2008;102:1053-4.
31. Gulati S, Maheshwari A. Atypical manifestations of dengue. Trop Med Int Health 2007;12:1087-95.
32. Zhang F, Kramer CV. Corticosteroids for dengue infection. Cochrane Database Syst Rev 2014;7:CD003488.
33. Tam DT, Ngoc TV, Tien NT, et al. Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial. Clin Infect Dis 2012;55:1216-24.
34. Noble CG, Chen YL, Dong H, et al. Strategies for development of dengue virus inhibitors. Antiviral Res 2010;85:450-62.
35. Nguyen NM, Tran CN, Phung LK, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis 2013;207:1442-50.
36. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012;380:1559-67.
37. Lanata CF, Andrade T, Gil AI, et al. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. Vaccine 2012;30:5935-41.
38. Leo YS, Wilder-Smith A, Archuleta S, et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 years: phase II randomized controlled trial in Singapore. Hum Vaccin Immunother 2012;8:1259-71.
39. Durbin AP, Kirkpatrick BD, Pierce KK, et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis 2013;207:957-65.
40. Capeding MR, Tran NH, Hadinegoro SR, et al; CYD14 Study Group. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014;384:1358-65.
41. Kularatne SA, Imbulpitiya IV, Abeysekera RA, et al. Extensive haemorrhagic necrosis of liver is an unpredictable fatal complication in dengue infection: a postmortem study. BMC Infect Dis 2014;14:141.